09.08.2022 • NewsAmgenMergers & Acquisitions (M&A)

Amgen Takes ChemoCentryx for $3.7 Billion

Amgen is beefing up its inflammatory diseases portfolio with an agreement to buy US biopharma ChemoCentryx for roughly $3.7 billion. The deal gives Amgen access to vasculitis treatment Tavneos.

"The acquisition of ChemoCentryx represents a compelling opportunity for Amgen to add to our decades-long leadership in inflammation and nephrology with Tavneos, a transformative, first-in-class treatment for ANCA-associated vasculitis," said Robert A. Bradway, chairman and chief executive officer at Amgen.

Last October, the US Food and Drug Administration approved Taveneos as an adjunctive treatment for adults with severe anti-neutrophil cytoplasmic autoantibody-associated (ANCA-associated) vasculitis – a group of multi-system autoimmune diseases with small vessel inflammation – in combination with standard therapy.

As well as the US, Tavneos is approved in other major markets, including the European Union and Japan. US Tavneos sales reached $5.4 million in the first quarter of 2022.

ChemoCentryx, which focuses on orally administered therapies for autoimmune diseases, inflammatory disorders and cancer, has three other early-stage drug candidates that target chemoattractant receptors in other inflammatory diseases and an oral checkpoint inhibitor for cancer.

Both companies’ boards of directors have unanimously approved the transaction, which is expected to close in the fourth quarter of 2022.

Last year, Amgen took over oncology company Five Prime Therapeutics for $1.9 billion, clinical-stage biotech Teneobio for up to $2.5 billion and Rodeo Therapeutics for $721 million.

Author: Elaine Burridge, Freelance Journalist

© shironosov/Getty Images
© shironosov/Getty Images

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.